{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:01:50Z","timestamp":1791302510032,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["BE2022371"],"award-info":[{"award-number":["BE2022371"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013058","name":"Jiangsu Provincial Key Research and Development Program","doi-asserted-by":"publisher","award":["BE2020344"],"award-info":[{"award-number":["BE2020344"]}],"id":[{"id":"10.13039\/501100013058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFA0710800"],"award-info":[{"award-number":["2020YFA0710800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFA0509000"],"award-info":[{"award-number":["2020YFA0509000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973463"],"award-info":[{"award-number":["81973463"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["3217110056"],"award-info":[{"award-number":["3217110056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170377"],"award-info":[{"award-number":["32170377"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171254"],"award-info":[{"award-number":["32171254"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32100253"],"award-info":[{"award-number":["32100253"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["020814380191"],"award-info":[{"award-number":["020814380191"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011444","name":"Jiangsu Provincial Key Laboratory for the Research and Utilization of Plant Resources, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["JSPKLB202201"],"award-info":[{"award-number":["JSPKLB202201"]}],"id":[{"id":"10.13039\/501100011444","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.intimp.2024.112359","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T22:46:30Z","timestamp":1716936390000},"page":"112359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-6019","authenticated-orcid":false,"given":"Bei","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirou Grace","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunyu","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianchi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4257","key":"10.1016\/j.intimp.2024.112359_b0005","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2024.112359_b0010","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1084\/jem.166.4.1055","article-title":"The interleukin 2 receptor. Functional consequences of its bimolecular structure","volume":"166","author":"Wang","year":"1987","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.112359_b0015","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.4049\/jimmunol.139.7.2308","article-title":"A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity","volume":"139","author":"Jacques","year":"1987","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112359_b0020","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"5751","key":"10.1016\/j.intimp.2024.112359_b0025","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1126\/science.1117893","article-title":"Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors","volume":"310","author":"Wang","year":"2005","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.intimp.2024.112359_b0030","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1073\/pnas.0511161103","article-title":"Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor","volume":"103","author":"Stauber","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"7877","key":"10.1016\/j.intimp.2024.112359_b0035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41586-021-03861-0","article-title":"An engineered IL-2 partial agonist promotes CD8(+) T cell stemness","volume":"597","author":"Mo","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.112359_b0040","doi-asserted-by":"crossref","first-page":"15373","DOI":"10.1038\/ncomms15373","article-title":"Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells","volume":"8","author":"Vazquez-Lombardi","year":"2017","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2024.112359_b0045","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20082824","article-title":"In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression","volume":"206","author":"Webster","year":"2009","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.intimp.2024.112359_b0050","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.4049\/jimmunol.181.10.6942","article-title":"Suppression of murine allergic airway disease by IL-2:Anti-IL-2 monoclonal antibody-induced regulatory T cells","volume":"181","author":"Wilson","year":"2008","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112359_b0055","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.immuni.2015.04.015","article-title":"Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms","volume":"42","author":"Spangler","year":"2015","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.intimp.2024.112359_b0060","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.4049\/jimmunol.1800578","article-title":"Engineering a single-agent cytokine\/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy","volume":"201","author":"Spangler","year":"2018","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112359_b0065","doi-asserted-by":"crossref","first-page":"e1102829","DOI":"10.1080\/2162402X.2015.1102829","article-title":"IL-2\/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?","volume":"5","author":"Tomala","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112359_b0070","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat. Commun."},{"issue":"30","key":"10.1016\/j.intimp.2024.112359_b0075","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results","volume":"41","author":"Diab","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112359_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003155","article-title":"Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate","volume":"10","author":"Merchant","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2024.112359_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.112359_b0090","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1182\/blood-2021-148885","article-title":"NL-201, a De Novo Agonist of IL-2 and IL-15 Receptors, Demonstrates Synergistic Antitumor Activity with Anti-PD-1 Checkpoint Inhibitor Therapy in a Preclinical Non-Hodgkin Lymphoma Model","volume":"138","author":"Huard","year":"2021","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2024.112359_b0095","first-page":"A540","article-title":"509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer","volume":"9","author":"Naing","year":"2021","journal-title":"J. ImmunoTherapy of Cancer"},{"key":"10.1016\/j.intimp.2024.112359_b0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1756-0500-2-135","article-title":"Size-exclusion chromatography can identify faster-associating protein complexes and evaluate design strategies","volume":"2","author":"Mayer","year":"2009","journal-title":"BMC. Res. Notes"},{"issue":"4","key":"10.1016\/j.intimp.2024.112359_b0105","first-page":"52","article-title":"Site-Specific protein PEGylation: application to cysteine analogs of recombinant human granulocyte colony-stimulating factor","volume":"3","author":"Rosendahl","year":"2005","journal-title":"BioProcess Int."},{"issue":"9","key":"10.1016\/j.intimp.2024.112359_b0110","first-page":"1415","article-title":"A targeted IL-15 fusion protein with potent anti-tumor activity","volume":"16","author":"Chen","year":"2015","journal-title":"CancerBiol Ther"},{"issue":"3","key":"10.1016\/j.intimp.2024.112359_b0115","article-title":"Assessing IL-2-induced STAT5 phosphorylation in fixed, permeabilized foxp3(+) treg cells by multiparameter flow cytometry","volume":"1","author":"Li","year":"2020","journal-title":"StarProtoc"},{"issue":"1","key":"10.1016\/j.intimp.2024.112359_b0120","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.1038\/s41598-021-87102-4","article-title":"Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity","volume":"11","author":"Ottolenghi","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2024.112359_b0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006611","article-title":"Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8(+) T cells","volume":"11","author":"LaPorte","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2024.112359_b0130","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1073\/pnas.252756299","article-title":"Binding of small molecules to an adaptive protein-protein interface","volume":"100","author":"Arkin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.intimp.2024.112359_b0135","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1021\/bi034138g","article-title":"Discovery and Characterization of Cooperative Ligand Binding in the Adaptive Region of Interleukin-2","volume":"42","author":"Hyde","year":"2003","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.intimp.2024.112359_b0140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.imbio.2012.02.009","article-title":"Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping","volume":"218","author":"Rojas","year":"2013","journal-title":"Immunobiology"},{"issue":"2","key":"10.1016\/j.intimp.2024.112359_b0145","doi-asserted-by":"crossref","first-page":"e0264353","DOI":"10.1371\/journal.pone.0264353","article-title":"Human IL-2Ra subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach","volume":"17","author":"Beig Parikhani","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2024.112359_b0150","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-021-24987-9","article-title":"An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism","volume":"12","author":"Ptacin","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2024.112359_b0155","doi-asserted-by":"crossref","first-page":"2293511","DOI":"10.1080\/2162402X.2023.2293511","article-title":"LFA-1 regulated by IL-2\/STAT5 pathway boosts antitumor function of intratumoral CD8(+) T cells for improving anti-PD-1 antibody therapy","volume":"13","author":"Shan","year":"2024","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.intimp.2024.112359_b0160","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/jps.21278","article-title":"The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics","volume":"97","author":"Fishburn","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.112359_b0165","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","article-title":"In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2","volume":"135","author":"Lotze","year":"1985","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112359_b0170","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/S0006-3495(03)74684-0","article-title":"Measurements of protein-protein interactions by size exclusion chromatography","volume":"85","author":"Bloustine","year":"2003","journal-title":"Biophys. J."},{"issue":"6","key":"10.1016\/j.intimp.2024.112359_b0175","doi-asserted-by":"crossref","first-page":"e1238538","DOI":"10.1080\/2162402X.2016.1238538","article-title":"Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines","volume":"8","author":"Perez Horta","year":"2019","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.intimp.2024.112359_b0180","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.4049\/jimmunol.1201895","article-title":"Human IL-2 mutein with higher antitumor efficacy than wild type IL-2","volume":"190","author":"Carmenate","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.112359_b0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cbpa.2014.09.006","article-title":"Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer","volume":"23","author":"Rosalia","year":"2014","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112359_b0190","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/s41419-018-1047-2","article-title":"A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2","volume":"9","author":"Chen","year":"2018","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.intimp.2024.112359_b0195","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112359_b0200","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","article-title":"IL-2Ralpha-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25(+)CD8(+) T cells","volume":"4","author":"Wu","year":"2023","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.112359_b0205","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2012.07.015","article-title":"A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours","volume":"49","author":"Gillessen","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.intimp.2024.112359_b0210","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1472-6750-8-58","article-title":"A comparative study of protein synthesis in in vitro systems: from the prokaryotic reconstituted to the eukaryotic extract-based","volume":"8","author":"Hillebrecht","year":"2008","journal-title":"BMC Biotechnol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112359_b0215","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1111\/cas.15127","article-title":"MK-6, a novel not-alpha IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.intimp.2024.112359_b0220","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41551-021-00797-8","article-title":"Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells","volume":"5","author":"Zhang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"7","key":"10.1016\/j.intimp.2024.112359_b0225","doi-asserted-by":"crossref","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","article-title":"Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy","volume":"12","author":"Charych","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2024.112359_b0230","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.4110\/in.2022.22.e5","article-title":"Advancements of common gamma-chain family cytokines in cancer immunotherapy","volume":"22","author":"Wolfarth","year":"2022","journal-title":"Immune Netw."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924008798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924008798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:39:48Z","timestamp":1791301188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924008798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":46,"alternative-id":["S1567576924008798"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112359","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112359"}}